0W8U Stock Overview
A biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Neovacs S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.00 |
| 52 Week High | €99.00 |
| 52 Week Low | €2.00 |
| Beta | -868.81 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0W8U | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -1.3% |
| 1Y | n/a | -14.6% | 8.9% |
Return vs Industry: Insufficient data to determine how 0W8U performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0W8U performed against the UK Market.
Price Volatility
| 0W8U volatility | |
|---|---|
| 0W8U Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0W8U has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0W8U's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 23 | Hugo Brugiere | www.neovacs.com |
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies.
Neovacs S.A. Fundamentals Summary
| 0W8U fundamental statistics | |
|---|---|
| Market cap | €87.92k |
| Earnings (TTM) | -€8.74m |
| Revenue (TTM) | €538.29k |
0.2x
P/S Ratio0.0x
P/E RatioIs 0W8U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0W8U income statement (TTM) | |
|---|---|
| Revenue | €538.29k |
| Cost of Revenue | €4.00m |
| Gross Profit | -€3.46m |
| Other Expenses | €5.28m |
| Earnings | -€8.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.86 |
| Gross Margin | -643.60% |
| Net Profit Margin | -1,624.30% |
| Debt/Equity Ratio | 1.4% |
How did 0W8U perform over the long term?
See historical performance and comparison